Help
Subscribe


GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy

 16 January 2018

Advanced search
GastroHep.com - the global online resource for all aspects of gastroenterology, hepatology and endoscopy Profile of Roy Pounder

Home

News  
Journals
Review Articles
Slide Atlas
Video Clips
Online Books
Advanced Digestive Endoscopy
Classical Cases
Conference Diary
PubMed
International GH Links
USA GH Links
National GH Links
National GI Societies
Other Useful Links




Emails on Gastroenterology and Hepatology
the National AIDS Treatment Advocacy Project
Visit the gastroenterology section of the EUMS

News

Cancer surveillance in primary sclerosing cholangitis is suboptimal

This month's issue of Inflammatory Bowel Diseases evaluates the costs of surveillance for colonic dysplasia in primary sclerosing cholangitis and colitis.

News image

fiogf49gjkf04

Patients with primary sclerosing cholangitis and colitis are at risk of developing dysplasia and colorectal cancer.

Consequently, annual surveillance colonoscopy with random biopsies is recommended.

Dr Remo Panaccione and colleagues from Canada determined the incidence of dysplasia or colorectal cancer to assess surveillance practices.

The research team also assessed the costs associated with surveillance of primary sclerosing cholangitis patients.

The team conducted a population-based study between 2000 and 2004 to identify all patients with a diagnosis of primary sclerosing cholangitis using regional databases.

Colonic histopathology reports of primary sclerosing cholangitis patients with colitis were reviewed.

The cost of surveillance to detect 1 case of dysplasia was $26,495
Inflammatory Bowel Diseases

The researchers determined the frequency of surveillance colonoscopies performed between 2000 and 2005.

In addition, the number of biopsies retrieved, and the presence of colorectal cancer or dysplasia was determined.

The cost of annual surveillance colonoscopy with 33 random biopsies to detect 1 additional case of dysplasia was calculated from a local costs database.

The research team identified 45 primary sclerosing cholangitis patients with ulcerative colitis or Crohn's disease.

The team noted that 11% of patients were diagnosed with low-grade dysplasia, dysplasia-associated lesion or mass, or colorectal cancer during the 5-year follow-up.

The incidence rate was 3 events per 100 person-years.

The researchers detected 2 of these lesions through surveillance, and 3 because of symptomatic presentation.

Only 36% of the expected number of surveillance colonoscopies were performed.

The median number of biopsies collected was 27.

The cost of surveillance to detect 1 additional case of dysplasia was $26,495.

Dr Panaccione's team concludes, "Despite a high rate of colorectal dysplasia or colorectal cancer among primary sclerosing cholangitis patients, surveillance was suboptimal."

Inflamm Bowel Dis 2007: 13(11): 1401-7
18 October 2007

Go to top of page Email this page Email this page to a colleague

 16 January 2018 
Anxiety about colonoscopy
 16 January 2018 
Thiopurines and colorectal neoplasia in IBD
 16 January 2018 
Bundle of care in GI cancer surgery
 15 January 2018 
Recent advances in hepatocellular carcinoma
 15 January 2018 
Ileostomy output using telemedicine
 15 January 2018 
Risks of death after liver transplants for liver cancer
 12 January 2018 
Surveillance protocols after colorectal cancer resection
 12 January 2018 
Biologic therapy by pregnant women with IBD and infant vaccines
 12 January 2018 
Biologic therapies for IBD in the USA
 11 January 2018 
Genetic risk factors in GERD
 11 January 2018 
Predictor of colorectal adenoma
 11 January 2018 
Ectopic pregnancy in IBD 
 10 January 2018 
Fecal immunochemical tests for colorectal cancer screening
 10 January 2018 
Risk factors for advanced NAFLD
 10 January 2018 
Dyspepsia prevalence with gastroesophageal reflux–type symptoms
 09 January 2018 
Screening intervals for people with family histories of colorectal cancer
 09 January 2018 
Financial impact of colorectal cancer
 09 January 2018 
Current practice and future research in autoimmune hepatitis
 08 January 2018 
Improving prognosis in patients with primary sclerosing cholangitis
 08 January 2018 
Reliability of the IBD index
 08 January 2018 
Aprepitant and nausea with gastroparesis
 05 January 2018 
Autoimmune pancreatitis and IBD
 05 January 2018 
Primary nonresponse to infliximab therapy
 05 January 2018 
Anesthesia assistance in outpatient colonoscopy
 04 January 2018 
Dietary polyphenols in the etiology of IBD
 04 January 2018 
Yoga vs low-FODMAP in IBS
 04 January 2018 
Local esophageal food allergen injections in eosinophilic esophagitis
 03 January 2018 
Population health management for IBD
 03 January 2018 
GERD in asthma and COPD
 03 January 2018 
Critical research gaps in colorectal cancer
 22 December 2017 
Costs of extrahepatic manifestations of Hep C
 22 December 2017 
Colonoscopy after colorectal cancer resection
 22 December 2017 
Cholera vaccine and risk of death in colorectal cancer
 21 December 2017 
Human oral microbiome and pancreatic cancer risk
 21 December 2017 
PPI and Alzheimer's disease
 21 December 2017 
Health management for IBD
 20 December 2017 
Incidence of biopsy-verified celiac disease
 20 December 2017 
Osteoporotic fractures in Barrett's esophagus
 20 December 2017 
Management of abnormal liver blood tests
 19 December 2017 
Family burden of pediatric Crohn's in the USA
 19 December 2017 
Alcohol abstinence and alcoholic hepatitis
 19 December 2017 
Early readmission in IBD patients
 18 December 2017 
Disease activity indices in celiac disease
 18 December 2017 
Colorectal cancer mortality with low-risk adenomas at colonoscopy
 18 December 2017 
Smoking behaviour predicted the risk of surgery in Crohn's
 15 December 2017 
Molecular classification of Crohn's disease
 15 December 2017 
Inflammatory diet pattern and colorectal cancer risk
 15 December 2017 
Medical cannabinoid legalization policy and vomiting
 14 December 2017 
PPIs and gastric cancer after H.pylori eradication
 14 December 2017 
H. pylori eradication therapies in countries with clarithromycin resistance
 13 December 2017 
Disease severity in NAFLD
 13 December 2017 
Tryptophan metabolism and IBD activity
 12 December 2017 
Risk factors in undiagnosed cirrhosis
 12 December 2017 
Monitored anesthesia care for outpatient GI endoscopy
 12 December 2017 
High-risk colorectal cancer patients
 06 December 2017 
Reflux-induced chronic cough 
 06 December 2017 
Systemic inflammatory response syndrome in acute-on-chronic liver failure
 06 December 2017 
Preventing hepatic encephalopathy-related readmissions
 05 December 2017 
Thiopurines and colorectal cancer in IBD
 05 December 2017 
Childhood obesity into adulthood

Blackwell Publishing


GastroHep.com is a Blackwell Publishing registered trademark
© 2018 Wiley-Blackwell and GastroHep.com and contributors
Privacy Statement
Disclaimer
About Us